In a ma­jor blow to vac­cine ef­forts, se­nior FDA lead­ers step­ping down

Mar­i­on Gru­ber

Two of the FDA’s most se­nior vac­cine lead­ers are ex­it­ing from their po­si­tions, rais­ing fresh ques­tions about the Biden ad­min­is­tra­tion and the way that it’s side­lined the FDA.

Mar­i­on Gru­ber, di­rec­tor of the FDA’s Of­fice of Vac­cines Re­search & Re­view and 32-year vet­er­an of the agency, will leave at the end of Oc­to­ber, and OVRR deputy di­rec­tor Phil Krause, who’s been at FDA for more than a decade, will leave in No­vem­ber. The news, first re­port­ed by Bio­Cen­tu­ry, is a mas­sive blow to con­fi­dence in the agency’s abil­i­ty to reg­u­late vac­cines.

The bomb­shell an­nounce­ment comes at a par­tic­u­lar­ly cru­cial mo­ment, as boost­ers and chil­dren’s shots are be­ing weighed by the reg­u­la­tor. The de­par­tures al­so come as the ad­min­is­tra­tion has re­cent­ly jumped ahead of the FDA’s re­views of boost­er shots, an­nounc­ing that they might be avail­able by the week of Sept. 20.

A for­mer se­nior FDA leader told End­points that they’re de­part­ing be­cause they’re frus­trat­ed that CDC and their ACIP com­mit­tee are in­volved in de­ci­sions that they think should be up to the FDA. The for­mer FDAer al­so said he’s heard they’re up­set with CBER di­rec­tor Pe­ter Marks for not in­sist­ing that those de­ci­sions should be kept in­side FDA. What fi­nal­ly did it for them was the White House get­ting ahead of FDA on boost­er shots.

FDA’s for­mer act­ing chief sci­en­tist Lu­ciana Bo­rio added on Twit­ter, “FDA is los­ing two gi­ants who helped bring us many safe and ef­fec­tive vac­cines over decades of pub­lic ser­vice.”

“These two are the lead­ers for Bi­o­log­ic (vac­cine) re­view in the US. They have a great team, but these two are the true lead­ers of CBER. A huge glob­al loss if they both leave,” For­mer BAR­DA di­rec­tor Rick Bright wrote, weigh­ing in on the news. “Dr. Gru­ber is much more than the Di­rec­tor. She is a glob­al leader. Vi­sion­ary mas­ter­mind be­hind glob­al clin­i­cal reg­u­la­to­ry sci­ence for flu, Ebo­la, Mers, Zi­ka, Sars-cov-2, many oth­ers.”

Phil Krause

In a let­ter from Marks to staff, he ex­plained:

Janet Wood­cock told End­points that she wish­es Gru­ber and Krause well and thanks them for their sig­nif­i­cant ser­vice.

Their Staying Power Lies in their Patient-Centricity

Map­ping the Fu­ture of De­cen­tral­ized Clin­i­cal Tri­als

Decentralized clinical trials (DCTs) were traditionally utilized in an isolated fashion prior to the COVID-19 pandemic. To continue their research within the constraints of the pandemic, sponsors and clinical investigators pivoted to a decentralized model out of necessity. At the onset, regulatory agencies offered some guidance on the digital approaches that are acceptable to ensure DCT approaches are applied in a way that maintains patient safety, as well as data quality and integrity.

Hit­ting a new record on drug ap­provals, the FDA of­fers a thumbs-up to an­oth­er atopic der­mati­tis con­tender

Five years after little Leo Pharma put up its dukes and $115 million in cash to acquire and advance tralokinumab for atopic dermatitis, the Danish biotech has crossed the regulatory finish lines with a year-end approval at the FDA.

The drug will be sold as Adbry and there’s no immediate word on pricing.

This is the 50th new drug approval from CDER this year, totting up to 60 for the year if you add 10 major biologic OKs to the mix. That marks a record number of new approvals from the agency, tipping the scales after hitting 59 in 2020 and 2018. And it’s an indication that despite a long litany of setbacks in CMC in other areas, the drumbeat of new approvals continues at chart-topping levels after the long and disastrous dry spell of the early 2000s — despite a global pandemic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

No­vavax breaks an­oth­er pledge for its Covid-19 vac­cine. And the US is re­port­ed­ly fret­ting about glob­al goals now

We’re talking weeks here, not months. — Stanley Erck, CEO of Novavax, to analysts on August 5.

In the U.S., we expect to submit our complete regulatory package to the FDA before the end of this year. — Erck on November 4.

Novavax expects to submit a request for EUA for the vaccine in the U.S. in one month… — Novavax statement on December 31.

You can add one more broken promise from Novavax $NVAX on its Covid-19 vaccine application to the FDA.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

Robert Davis, Merck CEO

FDA au­tho­rizes new Mer­ck Covid-19 pill de­spite sci­en­tist­s' con­cerns on its mech­a­nism of ac­tion

The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck.

While Pfizer’s antiviral may prove to be more effective, and Merck’s pill has left some scientists questioning the dangers behind its mechanism of action, molnupiravir will be another weapon in the armamentarium of Covid-19 treatments for the US in a time of need, as two mAb treatments from Regeneron and Eli Lilly are no longer effective against Omicron, and as supplies of a third mAb from Vir/GlaxoSmithKline are very limited.

Alzheimer's ex­perts call on FDA to pull Bio­gen's Aduhelm

Alzheimer’s disease researchers along with medical professors from Harvard and Johns Hopkins issued a formal statement Monday asking the FDA to quickly pull Biogen’s Aduhelm from the market.

“An accelerated withdrawal would mitigate some of the harm of its unwarranted accelerated approval,” they wrote to FDA, explaining how Aduhelm “did not meet the FDA’s own criteria for accelerated approval based on surrogate markers because amyloid plaque does not correlate well with symptoms, severity of disease or progression.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO

UP­DAT­ED: Not every­body is buy­ing it, but every­body is def­i­nite­ly talk­ing about a new Bio­gen buy­out re­port

A Korean business publication reported Wednesday that Samsung is in the process of making a buyout bid for Biogen, raising equal parts skepticism and anticipation around a possible deal.

The report from the Korea Economic Daily says that the Samsung Group – which has a long-term biosimilar partnership with Biogen – has offered to acquire Biogen for some $42 billion, a 20% improvement over the $35 billion recorded ahead of the report. That’s far less than what Biogen was trading for when hopes of a major windfall from their controversial Alzheimer’s drug Aduhelm still percolated.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

FDA adds an­oth­er drug OK to cap a record win list for 2021

With the clock ticking through the final hours of an eventful 2021, FDA regulators took the opportunity to squeeze in one more drug approval.

This time the nod went to Xeris for a rare disease treatment known as levoketoconazole, now approved for sale as Recorlev. The drug is designed to treat hypercortisolemia in patients suffering from Cushing’s syndrome. In late stage studies, researchers tracked a drop and normalization in cortisol levels in patients.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

Bridge­Bio shares go in­to melt­down mode as their lead PhI­II drug im­plodes at the fin­ish line

BridgeBio CEO Neil Kumar had all but reserved the champagne to celebrate the success of its big Phase III study for acoramidis, designed to stabilize transthyretin and slow or halt the progression of TTR amyloidosis. They had bought out full rights to the drug in late 2020 and borrowed the first $450 million of a $750 million loan, adding to a hefty debt load while confidently predicting a straight march to the FDA in 2022.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI and can ac­cel­er­at­ed ap­proval re­main in­tact?

It’s time for our holiday break here at Endpoints News, and like a lot of you, we’ve been prepping for 2022.

Anyone who’s spent some time in industry can tell you the past decade has shoved the drug-hunting field into the forefront of the world’s view of things, garnering tens of billions in investment as new technologies look to change the landscape of R&D. And anyone who qualifies for first-in-class and best-in-class can clean up.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 126,900+ biopharma pros reading Endpoints daily — and it's free.